|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0030705,
umls-concept:C0205314,
umls-concept:C0280100,
umls-concept:C0679622,
umls-concept:C0920321,
umls-concept:C1579259,
umls-concept:C1704259,
umls-concept:C1705987,
umls-concept:C1709060,
umls-concept:C2347619
|
|
pubmed:issue |
34
|
|
pubmed:dateCreated |
2008-11-27
|
|
pubmed:abstractText |
We conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities (DLTs), characterize the pharmacokinetic profile, and document any antitumor activity of ON 01910.Na, a new chemical entity that arrests cancer cells in G(2)/M by modulating mitotic regulatory pathways including polo-like kinase 1 (Plk1).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5504-10
|
|
pubmed:dateRevised |
2011-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:18955447-Aged,
pubmed-meshheading:18955447-Antineoplastic Agents,
pubmed-meshheading:18955447-Cell Cycle Proteins,
pubmed-meshheading:18955447-Cell Division,
pubmed-meshheading:18955447-Dose-Response Relationship, Drug,
pubmed-meshheading:18955447-Female,
pubmed-meshheading:18955447-G2 Phase,
pubmed-meshheading:18955447-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18955447-Glycine,
pubmed-meshheading:18955447-Humans,
pubmed-meshheading:18955447-Male,
pubmed-meshheading:18955447-Middle Aged,
pubmed-meshheading:18955447-Neoplasms,
pubmed-meshheading:18955447-Protein-Serine-Threonine Kinases,
pubmed-meshheading:18955447-Proto-Oncogene Proteins,
pubmed-meshheading:18955447-Sulfones,
pubmed-meshheading:18955447-Time Factors,
pubmed-meshheading:18955447-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
|
|
pubmed:affiliation |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA. antonio.jimeno@uchsc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
